Merck & Co., Inc. (MRK)[Tv]

Key Developments

• FDA approval of LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor, marks a transformative milestone in cardiometabolic therapy, positioning Merck as a leader in a high-growth, underserved cardiovascular market with significant commercial potential.
• Phase 3 INTerpath-001 trial success for intismeran autogene + Keytruda in resected high-risk melanoma delivers the first-ever successful Phase 3 result for an individualized mRNA neoantigen cancer vaccine—validating Merck’s pivot to next-generation personalized immuno-oncology and reshaping its long-term growth narrative.
• The FDA’s acceptance of the sBLA for ENFLONSIA, a pediatric RSV vaccine, with a March 22, 2027 PDUFA decision, represents a pivotal step in Merck’s diversification strategy and a potential inflection point for its future revenue base beyond oncology.
• Merck’s strategic licensing of HRS-5346, a cardiovascular drug developed entirely in China, signals a bold global innovation push but raises significant geopolitical and regulatory risks amid increasing U.S. scrutiny over Chinese technology and supply chain sovereignty.
• Merck’s $43 billion market cap surge in a single day following the intismeran trial success underscores a radical shift in investor perception—from a legacy blockbuster-dependent firm to a high-conviction growth engine in precision oncology.

Critical News